{"a":[{"_":"Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug","$":{"href":"/biotech/argenx-acquires-forte-22b-get-hands-phase-2-stage-vitiligo-drug","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Argenx announced the acquisition of Forte Biosciences for $2.2 billion to obtain a phase 2-stage drug candidate for vitiligo and celiac disease.
Clinical Trial Data
Phase
Phase 2
Importance:8/10
Sentiment:
0.60
M&Aacquisitionvitiligoceliac diseasephase 2
Related Companies
Read the original article
Published by FierceBiotech on July 27, 2026 6:10 AM